Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JX-594 Alone or With Irinotecan in Advanced Colorectal Cancer
NCT01394939Phase 2Completed
- Sponsor
- Jennerex Therapeutics
- Start
- Jan 2012
- Primary completion
- Jun 2015
- Modality
- Oncolytic Viruses
- Countries
- 3
01
Overview
Phase 2, open-label trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus in colorectal carcinoma (CRC) (4 arms), sponsored by Jennerex Therapeutics. Primary endpoint: Radiographic Response Rate. Started Jan 2012; status: completed.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT01394939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01394939.